
AI-generated summary
Anthropic was founded five years ago and is considered a leading company in AI research and development. The company is in direct competition with OpenAI and other AI companies.
Anthropic is making heavy losses, but the prospects are still good given the massive investments planned and the hype surrounding AI. Consequently, nothing should stand in the way of an IPO. The step could also be groundbreaking for the competition.
According to a stock market prospectus, the AI company Anthropic is aiming for a valuation of more than two trillion US dollars. This comes despite a reported net loss of $42 billion for 2025. The IPO would establish the company, which was founded just five years ago, as a benchmark for evaluating leading AI companies such as competitor OpenAI.
The net loss of nearly $42 billion included an accounting charge of about $34 billion resulting from the revaluation of financing. The company also plans to spend $518 billion on cloud and computing infrastructure in the coming years.
According to the prospectus, the company's sales grew twelvefold to almost $4.6 billion in 2025. At the same time, Anthropic posted a loss of more than $8 billion on an operating basis. Spending on computing power and infrastructure alone tripled last year to $7.33 billion.
Dangers from AI model
The IPO, expected to take place after the US midterm elections in November, will test investors' appetite for highly valued AI stocks. It follows the successful IPO of SpaceX, which was valued at $1.77 trillion.
The plans come as Anthropic faces findings from its own research that increasingly autonomous AI models can behave in unexpected and potentially harmful ways. Anthropic boss Dario Amodei has called on the AI community to slow down the pace of releasing new capabilities. Nevertheless, Anthropic launched its new model Opus 5.5 last week to keep up with competitor OpenAI and its GPT-6 Astra.
AI outlook — possibilities, not facts
Anthropic will conduct its IPO after the US midterm elections in November 2026.
Likely · Within months
Anthropic will continue to invest in AI research and development, despite warnings about autonomous models.
Very likely · Within years

Novo Nordisk will pay $300 million upfront for global development, production and commercialization rights to Jiangsu Hengrui Pharmaceuticals' experimental weight-loss pill HRS-1596, with possible additional payments up to $2.6 billion. The active ingredient acts on GLP-1 and GIP receptors and should be taken weekly. The license is valid worldwide except China, Hong Kong, Macau and Taiwan. Hengrui may receive royalties based on sales.
The Hornbach hardware store group recorded a six percent increase in sales to 3.8 billion euros and an adjusted operating profit (EBIT) of 285.6 million euros in the first half of the 2026/27 financial year, driven by high demand for seasonal products such as air conditioning units and shading items due to the hot summer.
According to the Handelsblatt report, the federal government is considering preventing the sale of the Hamburg freight forwarder Konrad Zippel to the Chinese state-owned company Cosco due to security concerns and the risk of strategic dependencies. A final ban has not yet been decided, but the authorities are moving towards it.

The Mainz-based company is closing three beach resorts and laying off 1,800 employees. The Tübingen plant is particularly in focus, where hundreds of millions of taxpayers' money were burned.

Biontech is reducing its German locations and cutting around 1,800 jobs after the end of the corona vaccine boom. At the same time, the federal government is selling its Biontech shares for around 130 million euros while trying to prevent the Chinese company Cosco from taking over the Hamburg logistics company Zippel in order to minimize geopolitical risks.
The article explains how investors can identify winners and losers in the stock market, why simply buying stocks is not enough and how ETFs help spread risk. He emphasizes that it is rarely too late to invest in stocks, but at the same time warns of current risks.